Needham & Company Remains Sidelined as Xcerra (XCRA) Reports In-Line 3Q Results

Go back to Needham & Company Remains Sidelined as Xcerra (XCRA) Reports In-Line 3Q Results

Pre-Open Stock Movers 06/06: (VBLT) (YGE) (ONTY) Higher; (DNAI) (ADMP) (MRTX) Lower (more...)

June 6, 2016 9:38 AM EDT

Today's Pre-Open Stocks Movers:

ProNAi Therapeutics, Inc. (Nasdaq: DNAI) 55% LOWER; announced disappointing interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

Adamis Pharmaceuticals Corporation (NASDAQ:... More

Xcerra (XCRA) Reports In-Line Q3 EPS; Offers Q4 Outlook

June 6, 2016 7:07 AM EDT

Xcerra (NASDAQ: XCRA) reported Q3 EPS of $0.00, in-line with the analyst estimate of $0.00. Revenue for the quarter came in at $82.24 million versus the consensus estimate of $81.4 million.

GUIDANCE:

Xcerra sees Q4 2016 EPS of $0.07-$0.10, versus the consensus of $0.09. Xcerra sees... More

Trading Radar for 6/6: Layne Christensen (LAYN), Xcerra (XCRA), United Natural Foods (UNFI), Thor (THO) Report

June 3, 2016 2:13 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:

Earnings:

Ability, Inc. (Nasdaq: ABIL) - consensus EPS $0.03
Xcerra (Nasdaq: XCRA) - consensus EPS... More